Ocaliva obeticholic acid regulatory update

FDA granted accelerated approval to an NDA from Intercept for Ocaliva obeticholic acid to treat primary biliary cholangitis (PBC).

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE